Table 2.
Patient Characteristics – CAD Risk Factors and Stress CMR Indication Details
| AF Group (N = 70) | SR Group (N = 70) | p-values | |
|---|---|---|---|
| Age – Median (IQR) | 73 (68–78) | 74 (67–79) | |
| Sex (%) | |||
| Male | 60 (85.7) | 59 (84.3) | |
| Female | 10 (14.3) | 11 (15.7) | |
| Diabetes (%) | 16 (22.9) | 15 (21.4) | 0.999 |
| Hypertension (%) | 38 (54.3) | 38 (54.3) | 0.999 |
| Smoking History (%) | |||
| Current Smoker | 3 (4.3) | 6 (8.6) | |
| Ex-smoker | 18 (25.7) | 18 (25.7) | |
| Non-smoker | 29 (41.4) | 37 (52.9) | |
| Missing Data | 20 (28.6) | 9 (12.9) | |
| Obesity (%)a | 27 (38.6) | 27 (38.6) | 0.999 |
| Dyslipidaemia (%) | 49 (70.0) | 54 (77.1) | 0.458 |
| Coronary Artery Disease (%) | 45 (64.3) | 46 (65.7) | 0.999 |
| Ischaemic Heart Disease (%) | 27 (38.6) | 22 (31.4) | 0.511 |
| Chest Pain (%) | 27 (38.6) | 42 (60.0) | 0.024* |
| Chest Pain Type (%)b | |||
| Typical | 13 (18.6) | 16 (22.9) | |
| Atypical | 5 (7.1) | 12 (17.1) | |
| Non-anginal | 9 (12.9) | 14 (20.0) | |
| Rate-control Drugs (%)c | 54 (77.1) | 42 (60.0) | 0.052 |
| Heart Rate - Median (IQR) Baseline Maximum Increase |
68 (61–74) 80 (72–88) 11 (8–19) |
61 (56–67) 80 (74–86) 19 (14–25) |
0.005* 0.698 <0.001* |
| Max. Adenosine Dose (%) 140 mcg/kg/min 180 mcg/kg/min 210 mcg/kg/min |
24 (34.3) 19 (27.1) 27 (38.6) |
42 (61.8) 17 (25.0) 9 (13.2) |
<0.001* |
| Intracardiac Measurements - Median (IQR) LVEF (%)d LV EDVIe LAVIf |
49 (39–54) 76 (65–100) 18 (14–21) |
55 (49–62) 71 (64–89) 11 (9–13) |
<0.001* 0.085 <0.001* |
| Symptoms During CMR (%) | 57 (82.6) | 63 (92.6) | 0.118 |
| Mortality (%)g | 6 (8.6) | 3 (4.3) | 0.453 |
a
Obesity defined as BMI>30.
b
NICE typical, atypical, and non-anginal definitions.1
c
Rate-control drugs recorded include β blockers, non-dihydropyridine calcium channel blockers, digoxin, and amiodarone.
d
Left ventricular ejection fraction
e
Left ventricular end-diastolic volume index (ml/m2)
f
Left atrium volume index (cm2/m2)
g
Between date of scan and study